Biogen and Xbrane announce commercialization and license agreement for biosimilar to treat rheumatoid arthritis
Under the terms of the agreement, Biogen will make an upfront payment of US $ 8 million to Xbrane
Under the terms of the agreement, Biogen will make an upfront payment of US $ 8 million to Xbrane
Newly formed Life Science Services business unit to offer fully integrated CDMO and Contract Testing Services
Biosynthetic Technologies produces estolides, a new class of biobased synthetic oils used in a number of applications, including motor oil, industrial lubricants, pharmaceuticals, and personal care.
Key takeaways of recent quarter & conference call highlights
ICICI Direct analysis of Dr Reddy’s Q3FY22 results
The management guided for ARV API & formulation demand to be normalised from Q4FY22 and reiterated the aspiration of US $ 1 billion in sales by FY23: ICICI Direct
Glenmark’s current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 46 ANDA’s pending approval with the U.S. FDA
According to IQVIA sales data for the 12-month period ending November 2021, the Ziac tablets, 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 mg market achieved annual sales of approximately US $ 30.3 million
The company develops sustainable botanical materials for agricultural and pharmaceutical applications
Astec LifeSciences has reported its financial performance for the quarter ended December 31, 2021
Subscribe To Our Newsletter & Stay Updated